Dr. Michael Ruffing
Boehringer Ingelheim Pharma
Referent:innen
Dr. Johannes Blümel
Paul-Ehrlich-Institut
Dr. Albrecht Gröner
PathoGuard Consult
Michael Schiffer
CSL Behring
Zielsetzung
The course aims to explain the complex nature of viruses that move between the concepts of life and death. It provides participants with a fundamental understanding of viral and pathogen safety in the pharmaceutical industry. Participants will acquire basic knowledge of virology, including the physiology of viruses, their replication cycles, transmission routes and resistance mechanisms. This knowledge is essential for risk assessment and the development of safety strategies.
In addition, the programme teaches advanced safety strategies for dealing with viruses and testing methods, including NGS (next generation sequencing) and other modern diagnostic methods. Participants will learn best practices for viral inactivation and validation to ensure products meet industry requirements and global regulatory frameworks such as ICH Q5A, the European Medicines Agency (EMA) and the European Pharmacopoeia.
The course also provides practical insights into the control of viral contamination, including risk mitigation strategies through facility segregation, risk analysis and contamination risk management. Finally, advanced virus detection methods, including NGS, and safety-related aspects of Advanced Therapy Medicinal Products (ATMP), such as gene and cell-based therapies, will be highlighted.
In addition, the programme teaches advanced safety strategies for dealing with viruses and testing methods, including NGS (next generation sequencing) and other modern diagnostic methods. Participants will learn best practices for viral inactivation and validation to ensure products meet industry requirements and global regulatory frameworks such as ICH Q5A, the European Medicines Agency (EMA) and the European Pharmacopoeia.
The course also provides practical insights into the control of viral contamination, including risk mitigation strategies through facility segregation, risk analysis and contamination risk management. Finally, advanced virus detection methods, including NGS, and safety-related aspects of Advanced Therapy Medicinal Products (ATMP), such as gene and cell-based therapies, will be highlighted.
Hintergrund
The past has shown us that the development and production of vaccines can also attract enormous public attention. This makes it all the more important, especially when it comes to approval and production under time pressure, that the quality standards of good manufacturing practice are observed.
Virus safety is one of the major concerns in the development and production of biopharmaceuticals and biologics. Huge efforts are undertaken to prevent viral contamination. A series of guidelines was dedicated to that topic exclusively.
For many people who are involved in the development and production of biopharmaceuticals and biologics the world of viruses is a “black box”.
Virus safety is one of the major concerns in the development and production of biopharmaceuticals and biologics. Huge efforts are undertaken to prevent viral contamination. A series of guidelines was dedicated to that topic exclusively.
For many people who are involved in the development and production of biopharmaceuticals and biologics the world of viruses is a “black box”.
Zielgruppe
This Education Course is directed to responsible personnel involved in the development and production of biopharmaceuticals and biologics
- Research & Development
- Quality Assurance
- Regulatory Affairs
- Production
- Engineering
- Quality Control
It is also useful for service providers, such as contract research organisations and contract manufacturers.
Presentations / Certificate
The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site.
After the event, you will automatically receive your certificate of participation.
After the event, you will automatically receive your certificate of participation.
Programm
Gesamtes Programm als PDF herunterladen
Elemental (basic) Virology
- Physiology (if you can use such a word)
- Replication cycles
- Vectors
- Resistance properties
Virus Safety Strategy: Approaches and Test Procedures
- Viral safety approach: Regulations and principles
- Virus testing concept
- Methods for detection of exogenous & endogenous virus
Virus Management: Methods for Inactivation and Validation Studies in Adventitious Virus Management
- Virus contamination of starting material for biologicals
- Dedicated virus reduction steps vs. manufacturing steps for protein purification and concentration
- Down scaling of manufacturing steps for virus clearance studies
- Virus clearance studies
- Virus spike preparation
- Controls as cytotoxicity / interference / balance /inctivation kinetic
- Virus detection methods – infectivity vs. NAT
- Robustness of virus reduction methods / DoE studies
Virus Safety: Regulatory Background
- ICH Guidelines (ICH Q5A)
- European Guidelines (EMEA)
- European Pharmacopoeia
- Risk assessment
- Clinical trials in Europe
Virus Contamination Control in pharmaceutical Production
- Adventitious agents contamination control strategies
- Facility segregation & risk Analysis
- Methods of risk assessment and minimization
- Case studies
Pathogen Safety Risk Management
- Strategies for ensuring product quality and safety
- What to consider and how to perform risk assessments regarding pathogen safety
- Deviations and change management
- Case studies
Next Generation Sequencing (NGS) - a powerful Technology for Virus Detection
- Technology & applications
- Regulations, e.g., in ICH Q5A & Ph. Eur.
Virus-based Advanced Therapy Medicinal Products (ATMPs)
- Applications
- Oncolytic viruses: Mode of action & adventitious virus safety approach
- AAV - efficient gene therapy vector
- Production of AAV for gene therapy
- Quality Control of AAV
- Clinical applications of AAV
Virus Safety Aspects of Advanced Therapy Medicinal Products (ATMP)
- Regulatory background/certification
- Gene therapy medicinal products
- Cell based medicinal products
Transmissible Spongiform Encephalopathy (TSE) – Biology & Regulatory
- Nature and transmission of TSE Agent
- TSE agent detection Methods
- Prion reduction Methods
- EU legislation / EMA note for guidance / reflection paper
- EDQM TSE Certification
| ECA-Member*: | € 1890,- |
| Non ECA Member*: | € 2090,- |
| EU/GMP Inspectorates*: | € 1045,- |
| APIC Member Discount*: | € 1990,- |
Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.
* auch unkompliziert per Kreditkarte bezahlbar
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
Weitere Termine online
Weitere Termine online nicht verfügbar
Aufzeichnung nicht verfügbar
This course is part of the GMP Certification Programme "ECA Certified Microbiological Laboratory Manager"
Haben Sie noch Fragen?
Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
E-Mail: info@concept-heidelberg.de
Für Lieferanten: Ausstellungs- und Sponsoringmöglichkeiten
Seminarprogramm als PDF
Sonderkonditionen DB BahnTeilnehmerstimmen - das sagen andere über unsere Seminare:
